Emodin enhances cytotoxicity of chemotherapeutic drugs in prostate cancer cells: The mechanisms involve ROS-mediated suppression of multidrug resistance and hypoxia inducible factor-1

Cancer Biology and Therapy

Volumn 7, Issue 3, 2008, Pages 468-475

  Huang, Xin Zhi ^a   Wang, Jie ^a   Huang, Chao ^a   Chen, Yu Ying ^a   Shi, Gui Ying ^a   Hu, Qing Shen ^a   Yi, Jing ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

DU 145 cells; Emodin; Hypoxia inducible factor 1; Multidrug resistance; Prostate cancer; Reactive oxygen species

Indexed keywords

ACETYLCYSTEINE; CISPLATIN; DOXORUBICIN; EMODIN; HYPOXIA INDUCIBLE FACTOR 1; PACLITAXEL; REACTIVE OXYGEN METABOLITE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; CANCER CELL CULTURE; CELL VIABILITY; CONTROLLED STUDY; CULTURE MEDIUM; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG EFFECT; FIBROBLAST; GENE; GENE EXPRESSION REGULATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HYPOXIA; MALE; MDR1 GENE; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; OXIDATIVE STRESS; PROSTATE CANCER; PROTEIN EXPRESSION; TRANSACTIVATION;

EID: 45349099696     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.7.3.5457     Document Type: Article

References (41)

1. Pervaiz S, Clement MV. Tumor intracellular redox status and drug resistance-serendipity or a causal relationship? Curr Pharm 2004; 10:1969-77.
2. Singh N, Azmi S, Sheriff A, Dhawan D, Khanna N. Differential sensitivity of murine myeloid FDC-P1 cells and apoptosis resistant mutant(s) to anticancer drugs. Mutat Res 2001; 474:105-12.
3. Furusawa S, Kimura E, Kisara S, Nakano S, Murata R, Tanaka Y, Sakaguchi S, Takayanagi M, Takayanagi Y, Sasaki K. Mechanism of resistance to oxidative stress in doxorubicin resistant cells. Biol Pharm Bull 2001; 24:474-9.
4. Renschler MF. The emerging role of reactive oxygen species in cancer therapy. Eur J Cancer 2004; 40:1934-40.
5. Bailey H H. L-S, R-buthionine sulfoximine: historical development and clinical issues. Chemico-Biological Interactions 1998; 111:239-54.
6. Maeda H, Hori S, Ohizumi H, Segawa T, Kakehi Y, Ogawa O, Kakizuka A. Effective treatment of advanced solid tumors by the combination of arsenic trioxide and L-buthinine-sulfoximine. Cell Death and Differentiation 2004; 11:737-46.
7. Chen Z, Woodburn KW, Shi C, Adelman DC, Rogers C, Simon DI. Photodynamic therapy with motexafin lutetium induces redox-sensitive apoptosis of vascular cells. Arterioscler Thromb Vasc Biol 2001; 21:759-64.
8. Husbeck B, Peehl DM, Knox SJ. Redox modulation of human prostate carcinoma cells by selenite increases radiation-induced cell killing. Free Radic Biol Med 2005; 38:50-7.
9. Kitamura K, Minami Y, Yamamoto K, Akao Y, Kiyoi H, Saito H, Naoe T. Involvement of CD95-independent caspase8 activation in arsenic trioxide-induced apoptosis. Leukemia 2000; 14:1743-50.
10. Yi J, Yang J, He R, Gao F, Sang H, Tang X, Ye RD. Emodin enhances arsenic trioxide-induced apoptosis via generation of reactive oxygen species and inhibition of survival signaling. Cancer Res 2004; 64:108-16.
11. Jing Y, Yang J, Wang Y, Li H, Chen Y, Hu Q, Shi G, Tang X, Yi J. Alteration of subcellular redox equilibrium and the consequent oxidative modification of nuclear factor kappaB are critical for anticancer cytotoxicity by emodin, a reactive oxygen species-producing agent. Free Radic Biol Med 2006; 40:2183-97.
12. Yang J, Li H, Chen YY, Wang XJ, Shi GY, Hu QS, Kang XL, Lu Y, Tang XM, Guo QS, Yi J. Anthraquinones sensitize tumor cells to arsenic cytotoxicity in vitro and in vivo via reactive oxygen species-mediated dual regulation of apoptosis. Free Radic Biol Med 2004; 37:2027-41.
13. Huang Q, Shen HM. Inhibitory effect of emodin on tumor invasion through suppression of activator protein-1 and nuclear factor-kappaB. Biochem Pharmacol 2004; 68:361-71.
14. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003; 3:721-32.
15. Comerford KM, Wallace TJ, Karhausen J, Louis NA, Montalto MC, Colgan SP. Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene. Cancer Res 2002; 62:3387-94.
16. Liao D, Johnson RS. Hypoxia: a key regulator of angiogenesis in cancer. Cancer Metastasis Rev 2007; 26:281-90.
17. Mabjeesh NJ, Amir S. Hypoxia-inducible factor (HIF) in human tumorigenesis. Histol Histopathol 2007; 22:559-72.
18. Belozerov VE, Van Meir EG. Inhibitors of hypoxia-inducible factor-1 signaling. Curr Opin Investig Drugs 2006; 7:1067-76.
19. Brown JM, Wilson WR. Exploiting tumour hypoxia in cancer treatment. Nature Rev Cancer 2004; 4:437-47.
20. Belozerov VE, Van Meir EG. Hypoxia inducible factor-1: a novel target for cancer therapy. Anticancer Drugs 2005; 16:901-9.
21. Nagle DG, Zhou YD. Natural product-based inhibitors of hypoxia-inducible factor-1 (HIF-1). Curr Drug Targets 2006; 7:355-69.
22. Kondo Y, Kuo SM, Watkins SC, Lazo JS. Metallothionein localization and cisplatin resistance in human hormone-independent prostatic tumor cell lines. Cancer Res 1995; 55:474-7.
23. Wartenberg M, Ling FC, Schallenberg M, Baumer AT, Petrat K, Hescheler J, Sauer H. Downregulation of intrinsic P-glycoprotein expression in multicellular prostate tumor spheroids by reactive oxygen species. J Biol Chem 2001; 276:17420-8.
24. van Brussel JP, Mickisch GH. Circumvention of multidrug resistance in genitourinary tumors. Int J Urol 1999; 5:1-15.
25. Aragon Ching JB, Dahut WL. Chemotherapy in Androgen-Independent Prostate Cancer (AIPC): What's next after taxane progression? Cancer Ther 2007; 5:151-60.
26. Fenig E, Nordenberg J, Beery E, Sulkes J, Wasserman L. Combined effect of aloe-emodin and chemotherapeutic agents on the proliferation of an adherent variant cell line of Merkel cell carcinoma. Oncol Rep 2004; 11:213-7.
27. Huang Q, Lu G, Shen HM, Chung MC, Ong CN. Anti-cancer properties of anthraquinones from Rhubarb. Med Res Rev 2007; 27:609-30.
28. Su YT ,Chang HL, Shyue SK, Hsu SL. Emodin induces apoptosis in human lung adenocarcinoma cells through a reactive oxygen species-dependent mitochondrial signaling pathway. Biochem Pharmacol 2005; 70:229-41.
29. Jung HA, Chung HY, Yokozawa T, Kim YC, Hyun SK, Choi JS. Alaternin and emodin with hydroxyl radical inhibitory and/or scavenging activities and hepatoprotective activity on tacrine-induced cytotoxicity in HepG2 cells. Arch Pharm Res 2004; 27:947-53.
30. Zhang L, Chang CJ, Bacus SS, Hung MC. Suppressed transformation and induced differentiation of HER-2/neu-overexpressing breast cancer cells by emodin. Cancer Res 1995; 55:3890-6.
31. Sarno S, Ruzzene M, Frascella P, Pagano MA, Meggio F, Zambon A, Mazzorana M, Di Maira G, Lucchini V, Pinna LA. Development and exploitation of CK2 inhibitors. Mol Cell Biochem 2005; 274:69-76.
32. Olsen BB, Bjørling Poulsen M, Guerra B. Emodin negatively affects the phosphoinositide 3-kinase/AKT signalling pathway: a study on its mechanism of action. Int J Biochem Cell Biol 2007; 39:227-37.
33. Cha TL, Qiu L, Chen CT, Wen Y, Hung MC. Emodin downregulates androgen receptor and inhibits prostate cancer cell growth. Cancer Res 2005; 65:2287-95.
34. Davies KJ. The broad spectrum of responses to oxidants in proliferating cells: a new paradigm for oxidative stress. IUBMB Life 1999; 48:41-7.
35. Kramer RA, Zakher J, Kim G. Role of the glutathione redox cycle in acquired and de novo multidrug resistance. Science 1988; 241:694-7.
36. Mansfield KD, Guzy RD, Pan Y, Young RM, Cash TP, Schumacker PT, Simon MC. Mitochondrial dysfunction resulting from loss of cytochrome c impairs cellular oxygen sensing and hypoxic HIF-alpha activation. Cell Metabolism 2005; 1:393-9.
37. Mansfield KD, Simon MC, Keith B. Hypoxic reduction in cellular glutathione levels requires mitochondrial reactive oxygen species. J Appl Physiol 2004; 97:1358-66.
38. Chandel NS, Maltepe E, Goldwasser E, Mathieu CE, Simon MC, Schumacker PT. Mitochondrial reactive oxygen species trigger hypoxia-induced transcription. Proc Natl Acad Sci USA 1998; 95:11715-20.
39. Goyal P, Weissmann N, Grimminger F, Hegel C, Bader L, Rose F, Fink L, Ghofrani HA, Schermuly RT, Schmidt HH, Seeger W, Hanze J. Upregulation of NAD(P)H oxidase 1 in hypoxia activates hypoxia-inducible factor 1 via increase in reactive oxygen species. Free Radic Biol Med 2004; 36:1279-88.
40. Wartenberg M, Hoffmann E, Schwindt H, Grunheck F, Petros J, Arnold JR, Hescheler J, Sauer H. Reactive oxygen species-linked regulation of the multidrug resistance transporter P-glycoprotein in Nox-1 overexpressing prostate tumor spheroids. FEBS Lett 2005; 579:4541-9.
41. Wartenberg M, Ling FC, Muschen M, Klein F, Acker H, Gassmann M, Petrat K, Putz V, Hescheler J, Sauer H. Regulation of the multidrug resistance transporter P-glycoprotein in multicellular tumor spheroids by hypoxia-inducible factor (HIF-1) and reactive oxygen species. FASEB J 2003; 17:503-5.